On October 20, 2025 CMU representatives participated in DRAP’s follow-up meeting to strengthen pharmacovigilance across public health programmes. The CMU delegation included Sania Nawaz Khan (Pharmacovigilance Officer), Hafiza Ayesha Hameed (Pharmacist – HIV/AIDS, TB & Malaria), Dr. Umair Malik (Treatment Specialist – HIV), Dr. Nazrul Islam (MDR Specialist) and Dr Ambreen (Program Officer HIV).
The session focused on practical steps to reinforce pharmacovigilance systems within national HIV, TB and malaria programmes and to ensure resilient monitoring of medicines safety across public health initiatives. Participants discussed coordination mechanisms, data flow and roles needed to sustain safety surveillance at programme level.
Strategic input was provided by WHO Consultant Dr. Jean-Christophe Delumeau, who guided collaborative planning aimed at meeting WHO GBT Level-3 benchmarks. Emphasis was placed on aligning systems with international standards and strengthening institutional capacity to detect, report and respond to adverse events.
Stakeholders highlighted the importance of closer collaboration between DRAP and programme teams to advance pharmacovigilance implementation in Pakistan. The meeting set the groundwork for follow-up actions and joint planning to enhance patient safety and the integrity of treatment programmes.
